Fig. 1 | Leukemia

Fig. 1

From: Characterisation of immunoparesis in newly diagnosed myeloma and its impact on progression-free and overall survival in both old and recent myeloma trials

Fig. 1

Levels of polyclonal immunoglobulin in MIX and MXI clinical trials. Data are presented for levels of polyclonal IgG (a, n = 1302), IgA (b, n = 2469) and IgM (c, n = 3226) at disease presentation in all myeloma patients without an IgG, IgA or IgM M-protein, respectively. For patients above normal ranges (NR), number of patients, percentage of patients and 95% confidence interval (CI) ranges for the percentage of patients are shown

Back to article page